Mitochondria occupy a central position in the biology of most eukaryotic cells, including all the cells of the cardio vascular system, because mitochondria have a major role in catabolic and anabolic metabolism, regulation of intracellular Ca 2+ homeostasis, initiation of inflamma tory reactions, and control of multiple pathways culmi nating in regulated cell death (RCD) [1] [2] [3] [4] . In line with this notion, the mitochondrial network is constantly sub jected to a tight quality control system that segregates dysfunctional mitochondria and delivers them to lyso somes for degradation 5, 6 . Such a mechanism, commonly known as mitophagy, involves not only the core molecu lar machinery for autophagy 7 but also a set of dedicated proteins that are required for the optimal recognition of damaged mitochondria [8] [9] [10] . A tight control on mitochondrial fitness is para mount for the preservation of cardiovascular homeo stasis for at least four reasons 11 . First, cardiomyocytes heavily rely on fatty acid driven oxidative phosphoryl ation for ATP production, at least in physiological set tings 12 . Thus, a decrease in the bioenergetic efficiency of the mitochondrial network can have a direct detri mental effect on the contractile capacity of cardiomyo cytes. Second, Ca 2+ fluxes are at the core of overall cardiac activity 1 . Therefore, defects in the capacity of the mitochondrial network (in conjunction with the endoplasmic reticulum) to regulate Ca 2+ homeostasis can alter cardiac functions such as electrical conduc tion. Third, physiological inflammatory homeostasis is particularly important not only for normal cardiac functions 13 but also for the preservation of vascular compartments 14 . Thus, damaged mitochondria accu mulating in the cytosol of cardiomyocytes or endothe lial cells can drive pathogenic inflammatory responses. Finally, the integrity of the cardiovascular system is cru cial for optimal contractile and circulatory functions 15 . Severe mitochondrial dysfunction and/or the accumu lation of permeabilized mitochondria (beyond a thresh old that depends on multiple parameters) can initiate several variants of RCD that culminate in pathological tissue loss (Fig. 1) .
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Severe mitochondrial dysfunction and/or the accumu lation of permeabilized mitochondria (beyond a thresh old that depends on multiple parameters) can initiate several variants of RCD that culminate in pathological tissue loss (Fig. 1) .
In line with these observations, mitochondrial defects have been involved, at least to some extent, in the patho genesis of a variety of cardiovascular disorders, includ ing (but not limited to) myocardial infarction (MI), cardiomyopathies of different aetiology, some forms of arrhythmia, hypertension, atherosclerosis, and other vascular conditions 16, 17 . Starting in the late 1990s, the identification of mitochondrial dysfunction as a cen tral aetiological determinant of cardiovascular disease (CVD) drove an intensive wave of preclinical and clini cal investigation aimed at the development of novel tar geted therapies 18 . Thus far, the results of such an effort have been disappointing, as no molecules specifically conceived to target mitochondria are currently avail able for use against CVD in clinical settings 19 . In this Review, we discuss the rationale for using mitochondria targeting agents (MTAs) in the treatment of CVD, dis sect the obstacles that have limited their development over the past 2 decades, and put forward strategies that might unleash the full potential of these promising -but hitherto unrealized -therapeutic tools.
Regulated cell death (RCD) . A form of cell death that relies on the activation of a genetically encoded machinery and which, therefore, can be retarded or accelerated with specific pharmacological or genetic interventions.
Autophagy
Evolutionarily conserved cellular process that culminates with the lysosomal degradation of ectopic, supernumerary, dysfunctional, or potentially dangerous cytoplasmic entities (of endogenous or exogenous derivation).
Therapeutic potential of MTAs
Targeting mitochondria from multiple angles has been associated with beneficial effects in a variety of experi mental CVD models (TAblEs 1,2). However, limited benefits have been documented in clinical trials investi gating the safety and efficacy of MTAs for the treatment of CVD, as discussed below.
Mitochondrial metabolism. Healthy cardiomyocytes satisfy their elevated energy needs by catabolizing fatty acids (via β-oxidation), branched chain amino acids, and, to a lesser extent, ketone bodies (via ketolysis) to fuel the tricarboxylic acid (TCA) cycle and drive ATP produc tion via the mitochondrial respiratory chain (box 1). By comparison, pyruvate derived from glycolysis contrib utes minimally to ATP synthesis in the healthy heart 11 . Such a predominantly mitochondrial metabolic profile shifts in the course of numerous cardiac pathologies. Heart failure (HF) is accompanied by a gradual decline in the bioenergetic reserve capacity of the myocardium, which -beyond a specific threshold -can no longer be compensated for by endogenous mechanisms 20 . In multiple variants of cardiomyopathy culminating with HF, cardiomyocytes undergo metabolic reprogramming involving decreased β oxidation and branched chain amino acid metabolism coupled with intracellular lipid deposition and increased glucose utilization [21] [22] [23] [24] . The TCA cycle intermediate succinate accumulates in the ischaemic myocardium, and such an accumulation is mechanistically linked to oxidative damage at reperfu sion 25 (see below). Along similar lines, TCA cycle activity is impaired 6 weeks after MI 26 , potentially representing an early maladaptive phase of the surviving tissue.
The molecular mechanisms underlying metabolic reprogramming in the diseased myocardium remain to be fully elucidated, although a role for specific tran scription factors has been postulated. For instance, nuclear receptor subfamily 2, group F, member 2 (NR2F2; also known as COUP TF2) is upregulated in patients with HF, and transgene driven Nr2f2 over expression in mice favours dilated cardiomyopathy accompanied by pathological metabolic remodelling 27 . Similarly, hypoxia inducible factor 1α (HIF1α) initi ates a transcriptional programme involving peroxisome proliferator activated receptor γ (PPARγ) that leads to increased glucose uptake and consequent lipid accumu lation, apoptotic cell death, and contractile dysfunction 21 .
Corroborating an aetiological role for this transcriptional module, ventricular specific deletion of Hif1a prevents pressure overloadinduced cardiomyopathy in mice 21 . Additional metabolic functions ensured (at least in part) by mitochondria are relevant for CVD, includ ing the folate cycle. An efficient folate cycle is indeed required for the optimal conversion of homocysteine into methionine, and defects in this pathway, including genetic variants in MTHFR (which encodes methy l enetetrahydrofolate reductase) are associated with an increased incidence of vascular disorders (such as thrombosis and atherosclerosis) secondary to, or at least paralleled by, homocysteine accumulation 28 . Of note, several mutations in mitochondrial or nuclear genes coding for components of the mitochondrial respiratory chain have been associated with familial cardiomyo pathies in humans 29 . Moreover, experimental interventions inducing respiratory defects in myocardial cells, such as the tissue specific deletion of Aifm1 (which encodes apoptosis inducing factor mitochondria associated 1) 30 or Tfam (which encodes mitochondrial transcription factor A; TFAM) 31 , result in spontaneous, early onset cardiomyopathy. Taken together, these observations exemplify the involvement of mitochondrial metabolic dysfunction in CVD.
Early clinical trials testing l carnitine supplemen tation, which (among other effects) favours the mito chondrial uptake of cytosolic fatty acids, in patients recovering from acute MI documented some degree of efficacy in reducing the incidence or severity of HF, left ventricular enlargement, arrhythmias, and car diac death 32, 33 . However, subsequent studies did not
Key points
• mitochondrial dysfunction is involved in the pathogenesis of multiple cardiovascular disorders, including myocardial infarction, cardiomyopathies of various aetiologies, arrhythmias, hypertension, and atherosclerosis.
• mitochondria are essential for the physiological activity of the cardiovascular system owing to their crucial role in bioenergetic and anabolic metabolism and their central position in intracellular Ca 2+ fluxes.
• In addition to losing their physiological functions, damaged mitochondria actively drive inflammatory responses and waves of regulated cell death that contribute to the pathogenesis of cardiovascular disease.
• An intensive wave of investigation attempted to develop mitochondria-targeting agents for preventing or treating cardiovascular disorders in patients, with rather dismal results.
• molecules with improved pharmacological features, precise mechanistic insights into mitochondrial processes, and reconsidering the pathogenesis of some cardiovascular disorders are instrumental for the development of mitochondria-targeting agents with clinical use.
conclusively confirm these observations 34, 35 . Moreover, oral l carnitine can be metabolized by the gut micro biota into trimethylamine N oxide (TMAO), a pro atherogenic molecule 36 . Accordingly, individuals with high l carnitine levels and concurrently high TMAO levels in the blood are at increased risk of CVD and major adverse cardiac events 36 . Thus, the clinical devel opment of l carnitine for the treatment of CVD seems to be at an impasse.
The β oxidation inhibitor etomoxir has also been investigated in patients with congestive HF, with incon clusive results 37, 38 . Conversely, perhexiline and trimetazi dine -which resemble etomoxir in their capacity to inhibit β oxidation (although to different degrees) -are currently approved in multiple countries (including Australia and Canada) as antianginal agents 39 . The thera peutic efficacy of perhexiline and trimetazidine has been proposed not to reflect a switch from fatty acid driven to glucose driven catabolism 40 but instead to entail an entire rebalancing of carbon and nucleotide phosphate fluxes 41 linked to autophagy activation 42 (see below).
Perhexiline is also effective (at least to some extent) in a subset of patients with cardiomyopathy 40, 43 , but not in patients with left ventricular hypertrophy undergoing cardiac surgery 44, 45 . Trimetazidine has been tested in multiple cohorts of patients with distinct cardiovascu lar disorders beyond angina, with variable degrees of efficacy [46] [47] [48] [49] . Nonetheless, in the USA (but not in other countries), the clinical development of perhexiline and trimetazidine has been discontinued, presumably owing to a fairly narrow therapeutic index 39 . 5Aminoimidazole4carboxamide ribonucleotide (AICAR; also known as acadesine) is an intermediate in the synthesis of inosine monophosphate that potently activates 5′AMP activated protein kinase (AMPK), a metabolic sensor regulating mitochondrial biogenesis, dynamics, and metabolism 50 . Despite some promis ing preliminary results 51, 52 , the clinical development of acadesine as a cardioprotective intervention in patients undergoing CABG surgery has been abandoned, at least in part owing to the lack of long term efficacy 53 . In sum mary, despite a robust rationale to target mitochondrial metabolism for the prevention or treatment of CVD, this therapeutic strategy remains largely unrealized.
Sirtuins.
Sirtuins are a family of NAD + dependent deacetylases and deacylases that control multiple aspects of cellular metabolism, including mitochon drial function and redox balance 54 . The mammalian genome encodes seven different sirtuins, three of which (SIRT3, SIRT4, and SIRT5) are localized to mitochon dria 54 . Pharmacological sirtuin activation mediates lifespan extending functions in multiple experimen tal models [55] [56] [57] , and defects in both mitochondrial and extramitochondrial sirtuins have been associated with a variety of cardiovascular disorders 58 . Sirt1 −/− mice are viable but have considerable developmental heart defects 59 . In Sirt1 +/− hearts, ischaemic preconditioning does not preserve cardiac function after ischaemiareperfusion injury, potentially linked to hyperacetyl ation of cytosolic proteins and consequent inhibition of autophagy 60, 61 , whereas myocardial Sirt1 overexpression has cardioprotective effects along with deacetylation of cytoplasmic proteins 60, 62 . Sirt3 −/− mice show signs of cardiac hypertrophy and interstitial fibrosis at 8 weeks of age, spontaneously develop age related cardiomyo pathy, and are more sensitive than their wild type littermates to hypertrophic stimuli, including aortic constriction 63, 64 . Such a susceptibility to cardiac hyper trophy reflects, at least in part, an increased propensity of the Sirt3 −/− myocardium to undergo regulated necro sis upon mitochondrial permeability transition (MPT) as a consequence of cyclophilin D (CypD; also known as PPIF) hyperacetylation 63, 64 (see below). Conversely, transgenic Sirt3 overexpression has robust cardioprotec tive effects in mice 63 . . Additionally , an intact mitochondrial network promotes the preservation of inflammatory homeostasis and tissue integrity by preventing the activation of signal transduction cascades that lead to the release of pro-inflammatory factors and regulated cell death. In addition to being accompanied by metabolic derangements and alterations in intracellular Ca 2+ fluxes, mitochondrial dysfunction favours the establishment of an inflammatory milieu and facilitates regulated cell death, which culminates with tissue loss. By efficiently eliminating dysfunctional mitochondria that originate as a consequence of physiological cellular functions or accumulate in the context of pathological cues, mitophagy has a major role in the preservation of cardiovascular homeostasis.
Folate cycle
biochemical pathway catalysing the cyclic conversion of tetrahydrofolate, 10-formyltetrahydrofolate (which feeds into purine synthesis), 5,10-methylenetetrahydrofolate, and 5-methyltetrahydrofolate (which feeds into methionine metabolism).
Mitochondrial permeability transition
(MPT). Rapid loss of the ionic barrier function of the inner mitochondrial membrane, culminating in mitochondrial breakdown and regulated necrosis. 63 , proficient autophagic responses 70 , and potentially the inhibition of MPT driven regulated necrosis 64, 71 (see below). Thus, sirtuins support cardiac fitness by affecting mitochondrial functions.
Sirtuins are activated by caloric restriction, which is also a potent inducer of autophagy, and a vast amount of literature is available on the multipronged beneficial effects of caloric restriction on cardiovascular health in humans, at least part of which are thought to depend mechanistically on sirtuins 72 . Additional sirtuin activa tors include the rather nonspecific natural polyphenols butein, honokiol, piceatannol, quercetin, and resver atrol 73, 74 as well as several synthetic sirtuin activating compounds, including SRT1720, SRT2104, and SRT3025 (REF. 57 ). All these molecules have been shown to medi ate beneficial effects in rodent models of CVD, and both SRT1720 and SRT2104 extend mouse lifespan [74] [75] [76] [77] . Similarly, dietary supplementation with nicotinamide mononucleotide (NMN; a precursor of NAD + ) medi ates potent cardioprotective effects in mouse models of cardiomyopathy and ischaemia-reperfusion injury via a SIRT1dependent or SIRT3dependent mecha nism [78] [79] [80] . The capacity of dietary resveratrol to limit the incidence or severity of various cardiovascular disorders (mostly in the context of type 2 diabetes mellitus) has been investigated in multiple clinical trials [81] [82] [83] , with inconclusive findings (often due to problematic study design). Still, no fewer than 20 non closed (status: not terminated, suspended, or withdrawn) clinical trials are currently registered at clinicaltrials.gov to investigate dietary supplementation with resveratrol in individuals with age associated morbidities (mostly type 2 diabetes) and cardiovascular conditions including non ischaemic cardiomyopathy (NCT01914081), hypertension (NCT01842399), atherosclerosis (NCT02998918), and endothelial dysfunction (NCT02256540). Results from a small randomized clinical trial including 40 patients with psoriasis (NCT01154101) suggest that SRT2104 is well tolerated 84 . The safety of SRT3025 has been investigated in healthy volunteers (NCT01340911), but to the best of our knowledge the results of this study have not been disseminated. Finally, the effects of dietary NMN sup plementation on cardiometabolic functions are currently being formally investigated (NCT03151239). Taken together, these observations suggest that, although mul tiple dietary interventions that activate sirtuins, including caloric restriction, resveratrol, and NMN (both of which are available over the counter), might mediate robust cardio protective effects, additional clinical testing is required for the establishment of official treatment protocols enabling the use of these agents for the treatment of CVD.
Mitochondrial dynamics. The mitochondrial network constantly undergoes remodelling owing to the mutually antagonistic activity of multiple proteins that promote fission, such as mitochondrial fission factor (MFF), mitochondrial fission 1 protein (FIS1), and dynamin1 like protein (DNM1L), and fusion, such as mitofusin 1 (MFN1), MFN2, and optic atrophy protein 1 (OPA1) 85 ( Fig. 2) . This process is paramount for the preservation of optimal mitochondrial functions in both physiologi cal and pathological conditions, at least in part because fission enables the mitophagic disposal of dysfunctional mitochondria 86 . Accordingly, multiple genetic defects impairing mitochondrial dynamics have been linked to CVD in experimental models.
The 93 . Similarly, mouse Mfn2 −/− hearts spontane ously develop dilated cardiomyopathy accompanied by mitochondrial hyperfragmentation, impaired con tractile performance, and insensitivity to β adrenergic stimulation 94, 95 . Further corroborating the importance of mitochondrial fusion for the preservation of cardio vascular homeostasis, adenovirus mediated delivery of Mfn2 to the mouse myocardium inhibits angiotensin II induced cardiomyopathy 96 . Interestingly, transgene driven overexpression of a non phosphorylatable MFN2 variant (MFN2AA) in the myocardium of newborn (but not adult) mice prevents normal mito chondrial maturation, accompanied by a switch from glucose driven to fatty acid driven metabolism, and leads to premature lethality, most probably as a conse quence of impaired mitophagy 97 (see below). Of note, physiological DNM1L dependent mitochondrial frag mentation is critical for cardiac adaptation to increased energy demands 98 . Moreover, conditional deletion of one copy of Dnm1l from the myocardium exacerbates pressure overloadinduced cardiomyopathy as well as ischaemia-reperfusion injury in mice as a consequence of mitophagy impairment 99, 100 . Altogether, these obser vations suggest that a balanced interplay between fission Attenuated decline in cardiac function coupled with decreased production of inflammatory cytokines and chemokines and decreased inflammatory cell infiltration into the myocardium after left coronary artery ligation 
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Reduced sensitivity to heart failure after I/R injury , at least partially dependent on reduced propensity to MPT Severe myocarditis and dilated cardiomyopathy associated with premature death 131 Δψ m , mitochondrial transmembrane potential; CaMKII, calcium/calmodulin-dependent protein kinase II; DN, dominant-negative; HFD, high-fat diet; IPC, ischaemic preconditioning; I/R , ischaemia-reperfusion; MCU, calcium uniporter protein, mitochondrial; MPT, mitochondrial permeability transition; NF-κB, nuclear factor-κB; RCD, regulated cell death; ROS, reactive oxygen species; SIRT3, sirtuin 3. and fusion is paramount for cardiovascular health as it preserves mitochondrial fitness in both physiologi cal and pathological conditions. Further corroborat ing this notion, the levels of various factors involved in the regulation of mitochondrial dynamics, includ ing FIS1, MFN2, and OPA1, are altered in the course of CVD [101] [102] [103] . Of note, MFN2 is also aetiologically involved in the proliferative arrest and death of vascu lar smooth muscle cells elicited by oxidative stress in rats 104 . In line with this notion, transgene driven Mfn2 overexpression reportedly prevents vascular smooth muscle cell proliferation and restenosis in rat models of arterial injury induced by balloon denudation of the left common carotid artery 105 . However, these effects seem to be independent of the role of MFN2 in the regulation of mitochondrial dynamics 104 . The chemical DNM1L inhibitor mdivi1 mediates cardioprotective effects in rodent models of cardiac ischaemia-reperfusion injury [106] [107] [108] and cardiomyo pathy 109, 110 , but the specificity of mdivi1 has been questioned 111 . Nonetheless, similar observations have been made with other DNM1L inhibitors such as P110 (REFs 112, 113 ) and dynasore 114 . A cell permeant peptide ena bling MFN2dependent mitochondrial fusion has also been developed 115 , but its biological activity in the cardio vascular system remains to be investigated. To the best of our knowledge, none of these agents has been tested in clinical settings thus far.
Mitophagy. Mitophagy constitutes a pillar in the mainten ance of mitochondrial homeostasis in both the healthy and diseased cardiovascular system 5, 6 . Accordingly, mul tiple defects in the molecular apparatus underlying pro ficient mitophagic responses have been associated with spontaneous CVD in experimental models 17 . Pink1
mice (lacking a kinase involved in the recognition of depolarized mitochondria) develop left ventricular dysfunction and cardiac hypertrophy by 2 months of age 116 . Deletion of Park2 (also known as Prkn; encod ing parkin RBR E3 ubiquitin protein ligase, a functional mitochondrial interactor of serine/threonine protein kinase PINK1, which is required for multiple variants of mitophagy) from the myocardium of adult mice causes a very mild cardiac phenotype in unstressed animals 117 . Conversely, Park2 ablation from the myocardium of neonate mice causes premature and rapidly lethal cardio myopathy associated with failed mitochondria matur ation (strikingly similar to the phenotype associated with MFN2AA expression) 97 . Similarly, knockout of park (the fly orthologue of Park2) in Drosophila melano gaster causes dilated cardiomyopathy that can be rescued by cardiomyocyte specific re expression of park 95, 118 . Bnip3l −/− mice lack a core component of the molecular apparatus for mitophagy and spontaneously develop cardiomegaly and contractile depression by 60 weeks of age, a pathological phenotype that is fur ther accelerated by the concomitant deletion of Bnip3 (coding for yet another protein involved in mitophagy) 119 . Genetic defects affecting autophagy also compromise cardiovascular homeostasis owing to the accumulation of dysfunctional mitochondria. This observation holds true for: cardiomyocyte specific deletion of Atg5 in adult mice, which causes lethal cardiac hypertrophy accom panied by disorganized sarcomere structure as well as mitochondrial misalignment and aggregation 120, 121 ; whole body deletion of Fbxo32 in mice, which is asso ciated with premature death owing to cardiac degener ation associated with deficient autophagic responses 122 ; and the Lamp2 −/− genotype, which causes a major lyso somal dysfunction that, in mice, drives a vacuolar myo pathy that affects cardiac and skeletal muscles, resembling Danon disease 123 . Of note, multiple genetic and phar macological interventions that impair mitochondrial dynamics impose at least some degree of mitophagic Box 1 | Principles of oxidative phosphorylation oxidative phosphorylation is a core bioenergetic process whereby reducing equivalents present in the mitochondrial matrix are sequentially used by four multiprotein complexes (generally referred to as respiratory complexes I-Iv) and two electron shuttles (namely, coenzyme Q (CoQ) and cytochrome c (Cyt c)) to generate an electrochemical H + gradient across the inner mitochondrial membrane that is harnessed in a controlled manner by the F 1 F o ATP synthase (also known as respiratory complex v) to catalyse the phosphorylation of ADP into ATP. The main substrates for oxidative phosphorylation are NADH, which provides electrons to complex I (also known as NADH dehydrogenase), and succinate, which provides electrons to complex II (also known as succinate dehydrogenase) via FADH 2 . Accordingly, FADH 2 can also fuel oxidative phosphorylation at the level of complex II. Both complex I and II deliver electrons to complex III (also known as CoQ:Cyt c oxidoreductase) via CoQ. However, only complex I transfers electrons onto complex III while also extruding H + ions from the mitochondrial matrix to the intermembrane space. Complex III transfers electrons to complex Iv (also known as Cyt c oxidase) via Cyt c, culminating with the reduction of o 2 into H 2 o. This last step is the reason why o 2 is critical for oxidative phosphorylation. Both complex III and complex Iv directly contribute to the generation of the mitochondrial transmembrane potential (Δψ m ). Finally, the F 1 F o ATP synthase uses a well-described rotatory mechanism to dissipate the Δψ m in a controlled manner, coupled with phosphorylation of ADP into ATP. This reaction requires ADP and inorganic phosphate (P i ), which are provided by the permeability transition pore components adenine nucleotide translocator (ANT) and phosphate carrier (PHC; also known as SlC25A3), respectively (see the figure; please note that stoichiometry is not respected for the sake of simplification). Importantly, the reaction catalysed by the F 1 F o ATP synthase is reversible. This reversibility implies that in ischaemic conditions the capacity of oxidative phosphorylation to drive ATP synthesis is impaired, owing to limited oxygen availability, and that high amounts of ATP are consumed by the F 1 F o ATP synthase to preserve the Δψ m . All metabolic intermediates entering the tricarboxylic acid (TCA) cycle, including (but not limited to) glucose-derived pyruvate and branchedchain amino acid-derived and fatty acid-derived acetyl-CoA and succinyl-CoA, can drive the synthesis of NADH and succinate in the mitochondrial matrix, thereby supporting oxidative phosphorylation. Fatty acid oxidation also supports oxidative phosphorylation via FADH 2 synthesis. of note, the cellular efficiency of oxidative phosphorylation depends on a variety of parameters, including the number of mitochondria per cell and their fragmentation state, the amount of respiratory complexes per mitochondrion, the supramolecular organization of respiratory complexes, substrate and o 2 availability, the expression of endogenous inhibitors, and local redox and pH conditions 339, 340 . incompetence 86 . These two processes are so intimately interconnected that mechanistically ascribing the pheno type to either of the alterations is difficult. Additional genetic alterations that trigger CVD in rodents, such as cardiac deletion of Tfrc (coding for the transferrin receptor) 124 , are associated with mitophagic defects. Moreover, genetic defects that improve mitophagic proficiency, such as whole body absence of Trp53 (also known as Tp53; coding for a master regulator of cellu lar biology that inhibits autophagy in physiological settings), decelerate spontaneous cardiac ageing 125 . Taken together, these observations exemplify the critical role of mitophagy in the preservation of physiological cardiovascular homeostasis. That said, Park2 deletion seems to rescue, at least in part, the lethal phenotype of Dnm1l deletion in the adult myocardium 117 , suggesting a role for uncontrolled mitophagy in the detrimental phenotype imposed by defects in mitochondrial fission (see above).
Multiple genetic defects impairing mitophagic profi ciency aggravate disease severity in experimental models of CVD 17 . Bnip3l −/− Bnip3 −/− hearts are highly sensitive to decompensation induced by pressure overload 119 . Homozygous or heterozygous deletion of Atg5 from the mouse myocardium exacerbates cardiomyopathy driven by pressure overload 120 and angiotensin II administra tion 126 . Similarly, mice bearing Atg5 −/− monocytes are more susceptible to develop atherosclerotic lesions in response to a high fat diet or Ldlr deletion than mice with wild type monocytes 127, 128 . Mice engineered to overexpress Rheb, which encodes the endogenous autophagy inhibitor RAS homologue enriched in brain (RHEB), in the myocardium are more susceptible to car diac ischaemia-reperfusion injury than wild type mice, a detrimental phenotype that can be partially rescued by administration of the pharmacological autophagy acti vator rapamycin 129, 130 .
Dnase2a
−/− mice, which lack a lyso somal nuclease (deoxyribonuclease 2α) that is involved in the autophagic degradation of mtDNA released upon mitochondrial damage, are extremely sensitive to pressure overloadinduced cardiomyopathy, at least in part owing to exaggerated inflammatory responses in the myocardium 131 (see below). Interestingly, cathelicidin antimicrobial peptide (CAMP) can bind mtDNA to limit its degradation by DNase 2α (DNASE2α), which has been associated with exacerbated atherosclerosis in Apoe −/− mice 132 . Whole body overexpression of Atg7 (encod ing a core component of the autophagic machinery) restrains cardiac hypertrophy and extends survival in a mouse model of desmin related cardiomyopathy 133 . The Trp53 −/− genotype limits both ischaemia-reperfusion injury and doxorubicin cardiotoxicity in mice, potentially owing to reduced myocardial susceptibility to RCD (see RCD section below), and improved mitophagy 125, 134 . Multiple other genetic alterations that mediate beneficial effects in experimental models of CVD are associated with superior mitophagic responses (although precise mech anistic links are missing), including the Stk4 −/− genotype, which limits cardiac ischaemia-reperfusion injury 135 , and the whole body deletion of Lclat1, which mitigates hypertrophic cardiomyopathy induced by thyroid hyper stimulation 136 . Moreover, multiple cardioprotective inter ventions including hypothermia and the administration of glucagon like peptide 1 receptor (GLP1R) agonists have been shown to promote autophagy (at least in some cell types), correlating with reduced amounts of RCD 137, 138 .
Conversely, Pgam5
−/− mice are more susceptible to car diac ischaemia-reperfusion injury than their wild type littermates along with a whole body defect in mitophagy, potentially linked to the capacity of phosphoglycerate mutase family member 5 (PGAM5) to regulate DNM1L dependent fission 139 . Similarly, mice with an endothelial cell specific deletion of Pdcd10 spontaneously develop a syndrome resembling cerebral cavernous malformations, accompanied by robust autophagic defects 140 . Thus, the optimal elimination of damaged mitochondria by mito phagy is fundamental for the cardiovascular system to control potentially pathogenic challenges.
Interestingly, the role of beclin 1 (BECN1), a core component of the autophagic machinery that par ticipates in multiple instances of mitophagy 7 , in the preservation of cardiovascular homeostasis in patho logical settings is rather controversial. Indeed, whereas BECN1 has been attributed a cardioprotective role in some models of CVD 99, 141 , Becn1 +/− rodents consist ently exhibited low sensitivity to potentially cardiotoxic challenges [142] [143] [144] . Although the reasons for this apparent discrepancy remain to be formally elucidated, linking them to emerging autophagy independent functions of BECN1 in RCD regulation is tempting 145 . Further corroborating the critical role of mitophagy in cardio vascular homeostasis, ischaemic preconditioning has been associated with the translocation of PARK2 to depolarized mitochondria and consequent initiation of their autophagic disposal 146 . Moreover, the expression levels of components of the mitophagic apparatus such as PINK1 decrease in patients with CVD 116 , and HF is more frequent in individuals with mitophagy defects (as in patients with Parkinson disease) 147 .
Sirtuin activators such as caloric restriction and resveratrol are potent activators of autophagy, adding to multiple lines of evidence intimately linking the sirtuin system and autophagic responses. Additional pharma cological agents that promote mitophagy or autophagy have been shown to mediate beneficial effects in rodent models of CVD 17 . These include the natural polyamine spermidine, an inhibitor of the acetyltrans ferase E1Aassociated protein p300 (EP300) [148] [149] [150] , and the natu ral macrolide rapamycin (also known as siroli mus), which inhibits the master suppressor of auto phagy mechanistic target of rapamycin (mTOR) [151] [152] [153] [154] . Conversely, systemic administration of nonspecific inhibitors of autophagy such as 3methyladenine, which targets multiple variants of phosphatidylinositol 3kinase (PI3K), and bafilomycin A1, which suppresses lysosomal functions, generally increases disease sever ity in rodent models of CVD, including ischaemiareperfusion injury 153, 155, 156 . Interestingly, sirolimus is largely employed in drug eluting stents to prevent restenosis after percutaneous coronary intervention 157 . Although this use originated from the potent antipro liferative and anti inflammatory activity of sirolimus 158 , it cannot be excluded that the therapeutic benefits of this strategy involve, at least in part, the induction of autophagy, which reportedly stimulates the degra dation of oxidized LDL 159 and might also favour the clearance of macrophages from the atherosclerotic plaque 160, 161 . Moreover, multiple FDA approved agents that mediate beneficial effects on the cardiovascular system, including aspirin (which is widely used as an anti inflammatory and anticoagulant) 162 , statins (which are currently used to lower circulating levels of choles terol and triglycerides) 163 , and suberanilohydroxamic acid (SAHA; a histone deacetylase inhibitor used for the treatment of cutaneous T cell lymphoma) 164, 165 , trigger proficient autophagic responses in the myocardium.
Despite the robust links between mitophagy and/or autophagy activation and improved cardiovascular homeostasis in health and disease, targeting the under lying molecular apparatus with specific pharmaco logical intervention has proved to be challenging 130 . Accordingly, no clinical trials are currently investigating the therapeutic potential of mitophagy and/or autophagy modulators beyond calorie restriction and sirolimus in patients with CVD. 166 . In physiological conditions, mitochondrial Ca 2+ uptake is mediated by calcium uniporter protein, mitochondrial (MCU) 167, 168 .
Ca

Conversely, Ca
2+ efflux from the mitochondrial matrix relies primarily on the Na + /Ca 2+ antiporter SLC8B1
Cerebral cavernous malformations
Cerebrovascular disease characterized by enlarged and leaky capillaries that predispose to seizures, focal neurological deficits, and fatal intracerebral haemorrhages.
Histone deacetylase inhibitor
Member of a fairly new class of targeted anticancer agents that operate by derepressing histone acetylation, resulting in the epigenetic reconfiguration of multiple transcriptional modules.
(also known as NCLX) 169 . Although mild, transient elevations of mitochondrial Ca 2+ levels support oxida tive phosphorylation and ATP synthesis 170 , persistent Ca 2+ overload favours MPT 171 . In line with this notion, the transgene driven overexpression of a leaky variant of RYR2 in the mouse myocardium exacerbates the cardiotoxic effects of ischaemia-reperfusion injury and causes mitochondrial Ca 2+ overload in cardiomyo cytes 172 . Moreover, in multiple cell types, including cardiomyocytes, MCU deficiency confers resistance to MPT driven by mitochondrial Ca 2+ overload 173, 174 , and the conditional deletion of Mcu from adult cardio myocytes mediates cardioprotective effects against ischaemia-reperfusion injury in vivo 174, 175 . However, the hearts from Mcu −/− mice, as well as mouse hearts expressing a dominant negative variant of MCU, are as susceptible to ischaemia-reperfusion injury ex vivo as their wild type counterparts 173, 176 . The reasons under lying this apparent discrepancy remain to be elucidated. As a possibility, the contribution of mitochondrial Ca 2+ overload to MPT might be limited when ischaemiareperfusion injury is imposed ex vivo. Irrespective of this conundrum, MCU seems to be required for opti mal cardiac responses to acute physical demands 174, 175 . Importantly, deletion of Slc8b1 from adult mouse cardio myocytes provokes sudden death as a consequence of mitochondrial Ca 2+ overload leading to widespread MPT driven necrosis of the myocardium 177 . Conversely, Slc8b1 overexpression mediates robust cardioprotec tion in mouse models of cardiac ischaemia-reperfusion injury 177 . These observations exemplify the impor tance of mitochondrial Ca 2+ fluxes for cardiovascular homeostasis in health and disease.
Further corroborating the crucial role for intracel lular Ca 2+ homeostasis in cardiac physiology, genetic defects in plasma membrane L type Ca 2+ channels are known to impair cardiac signal conduction, potentially favouring the development of arrhythmia 178 . Moreover, hyperactivation of the cytosolic Ca 2+ responsive enzyme calcium/calmodulin dependent protein kinase II (CaMKII) has been aetiologically linked to a variety of cardiovascular disorders, often reflecting the ability of CaMKII to regulate mitochondrial functions. Mice engineered to overexpress an endogenous inhibitor of CaMKII in cardiomyocytes are protected from ischaemiareperfusion injury in vivo 179 , presumably reflecting the capacity of CaMKII to trigger MCU dependent mito chondrial Ca 2+ overload, blunt antioxidant defences, and trigger DNM1L dependent mitochondrial frag mentation [179] [180] [181] [182] . Deletion of Camk2d (encoding one of the CaMKII subunits) attenuates pathological maladaptation in a genetic mouse model of decom pensating cardiac hypertrophy 182 . Moreover, CaMKII seems to participate in the pathogenesis of athero sclerotic plaques 183 , although the underlying molecular mechanisms remain to be unveiled.
Although 169 . That said, NCLX inhibitors never entered clinical development, presumably owing to specificity issues, because these compounds also inhibit the plasma membrane Na + /Ca 2+ antiporter SLC8A1 186 . Chemical inhibitors of MCU including DS16570511 have also been identified 187 , but whether MCU inhibition constitutes a valid therapeutic objective for the treatment of CVD remains controversial. Supporting caution over this approach, the anticancer agent mitoxantrone, which is associated with robust cardiotoxic effects in some patients, potently inhibits MCU (potentially contribut ing the adverse effects of this chemotherapeutic) 188 . The necroptosis inhibitor Necrox5 has also been suggested to mediate beneficial effects via MCU inhibition 189 , but the specificity of this molecule remains to be deter mined. Finally, a panel of CaMKII inhibitors is available for investigational purposes, including competitive and noncompetitive inhibitors of ATP or substrate binding, agents that disrupt calmodulin binding, and agents that mimic endo genous CaMKII blockers 190 . Although many of these agents mediate consistent beneficial effects in animal models of CVD (reviewed previously) 190 , none of them has entered clinical development.
Oxidative stress. Mitochondria generate reactive oxy gen species (ROS) as a normal by product of oxidative phosphorylation, and physiological ROS levels regulate multiple cardiovascular processes, including (but not limited to) metabolic functions in the myocardium and endothelial permeability in vessels 191 . However, mitochondrial dysfunction is generally associated with massive ROS overgeneration (box 2), which (espe cially when cellular antioxidant defences are lowered) causes oxidative damage to macromolecules, thereby favouring the establishment of local inflammation 2 and initiating multiple variants of RCD including MPT driven regulated necrosis and ferroptosis 171, 192 . The human failing myocardium reportedly has more than twofold higher levels of superoxide anion than the healthy myocardium 193 . Similar observations have been made in the context of diabetic and hypertensive cardio myopathy 194, 195 . Moreover, markers of oxidative damage to lipids 196 , nucleic acids 197 , and proteins 198 have been documented in the circulation or in the myocar dial tissue of patients with MI or HF (and in animal models of these conditions) 199 . Finally, myocardial mitochondria exhibit increased oxidative damage in aged versus young rats 200 , and the mitochondrial net work of rat endothelial cells produces increased levels of H 2 O 2 with ageing 201 . These observations suggest that oxidative stress is involved in multiple forms of CVD, including ageing associated cardiovascular disorders. Corroborating an aetiological role for ROS overpro duction in at least some variants of CVD, the absence of one copy of Sod2 (which encodes a mitochondrial superoxide dismutase) aggravates atherosclerosis (Fenton reaction) (see figure; please note that stoichiometry is not respected for the sake of simplification). Physiological levels of reactive oxygen species (RoS) are involved in the regulation of several biological processes, including intracellular signalling, adaptation to hypoxia, autophagy, and both adaptive and innate immunity 341 . However, RoS levels that exceed endogenous antioxidant capacities cause extensive macromolecular damage to DNA, proteins, and lipids, generally leading to cellular senescence (the permanent proliferative inactivation of a cell damaged beyond repair) or regulated cell death.
In the hypoxic myocardium, electrons cannot flow normally through the respiratory chain because o 2 availability is limited. This impairment favours the acquisition of a reduced state by respiratory complexes, which enables electron leak, o 2
•− synthesis, and oxidative damage to the respiratory chain. At tissue reperfusion, restored oxygen availability drives an abrupt increase in electron flow through damaged respiratory complexes, which is associated with a burst in o 2
•− production. Reperfusion is the phase at which mitochondria are most sensitive to RoS-mediated mitochondrial permeability transition because the low pH associated with ischaemia potently inhibits mitochondrial permeability transition. It has been proposed that uncoupling, the process whereby the transfer of electrons along the respiratory chain occurs in the absence of net extrusion of H + ions from the mitochondrial matrix, leading to decreased mitochondrial transmembrane potential and therefore to reduced sensitivity of respiratory complexes to hypoxia-mediated reduction, might have evolved as a physiological barrier against oxidative damage rather than as a thermogenic process 342 . GSSG, glutathione disulfide. 202 . Placing mice under progressive respiratory hypoxia after ischaemiareperfusion limits ROS production because hypoxia induces a robust regenerative response with decreased myocardial fibrosis and improvement of left ventricular systolic function 203 . Moreover, cardiomyocyte specific deletion of Txnrd2 (which encodes thioredoxin reduc tase 2) from mouse embryos leads to fatal dilated cardio myopathy 204 . Interestingly, imposing the same genetic defect on adult mice generates a much milder cardiac phenotype resembling accelerated cardiac ageing 205 . This finding suggests that the embryonic and neonatal myocardium and its adult counterpart have different sensitivity to oxidative stress.
The possibility to use antioxidants (including mol ecules available over the counter as dietary supplements) for the treatment of CVD drove an intense wave of preclinical and clinical investigation spanning the past 2 decades. Coenzyme Q 10 , α tocopherol (vitamin E), ascorbic acid (vitamin C), and β carotene (the precur sor of vitamin A) have all been clinically tested for the treatment or prophylaxis of HF 206, 207 , high risk heart surgery 208 , acute MI [209] [210] [211] [212] [213] [214] , and atherosclerosis 215, 216 . The majority of these studies confirmed that active levels of antioxidants can be achieved in the circulation of patients with CVD, although most often this is not asso ciated with measurable clinical benefits, perhaps with the exception of coenzyme Q 10 supplementation for the treatment of moderate tosevere HF 206 . Some clinical tri als are ongoing to test the clinical activity of coenzyme Q 10 or its reduced counterpart (ubiquinol) in patients with HF (NCT03133793, NCT01925937, NCT02779634, and NCT02847585), cardiac arrest (NCT02934555), and atherothrombosis (NCT02218476) as well as the cap acity of ascorbic acid to prevent atrial fibrillation after CABG surgery (NCT03123107).
Promising preclinical results have been obtained with mitochondria targeted antioxidants, including elamipretide (also known as Bendavia, MPT131, and SS31), mitoQ, and mito TEMPO, in animal models of MI 217 , hypertensive cardiomyopathy 195, [218] [219] [220] , HF 221 , ischaemia-reperfusion injury [222] [223] [224] , pathological tissue remodelling after MI 225 , and atherosclerosis 226 , foster ing the initiation of multiple clinical trials. Both the EVOLVE (NCT01755858) and the EMBRACE STEMI (NCT01572909) studies, evaluating the capacity of elamipretide to limit restenosis after angioplasty of the renal or coronary artery, respectively, did not report clinical benefits 227, 228 . Conversely, high dose elami pretide decreased left ventricular end diastolic vol ume and end systolic volume in HF 218, 221 with reduced ejection fraction, pointing to (at least some degree of) clinical efficacy 229 . Elamipretide is still being investi gated in Europe for its therapeutic effects in patients with HF (NCT02914665 and NCT02788747), whereas in the USA, increased attention is being dedicated to the possibility of using elamipretide for the treat ment of mitochondrial disorders (such as myopa thies and retinopathies). Along similar lines, mitoQ is mostly being investigated in clinical settings other than CVD.
Inflammation. The major role of mitochondria in the establishment of innate inflammatory responses that contribute to the pathogenesis of CVD is now clear 230 . This observation reflects the key contribution of mito chondrial metabolism and ROS production to multiple immune functions (which is beyond the scope of this Review) 231 , and the fact that mitochondria contain a large amount of endogenous molecules that can act as damage-associated molecular patterns (DAMPs) upon release 232, 233 . These molecules include (but potentially are not limited to) ROS, mtDNA, ATP, and cardio lipin 233 . Both ROS and mtDNA (alone or complexed with TFAM) can stimulate inflammatory responses from the cytosol, owing to their capacity to stimulate the release of IL1β, IL18, and type I interferon upon activation of the inflammasome and the stimulator of interferon genes protein (STING; also known as TMEM173) 234, 235 . Moreover, extracellular mtDNA can drive granulocyte degranulation upon binding to Toll like receptor 9 (TLR9) 236 . Extracellular ATP released in the course of RCD operates both as a chemoattractant and as an immunostimulant for myeloid cells 237 . Finally, cardiolipin can favour the activation of γδ T lymphocytes via a CD1D dependent mechanism 238 . Although not all these processes have been implicated in the pathophys iology of CVD, these observations exemplify well how mitochondrial dysfunction in the cardiovascular system, especially in the presence of a mitophagic defect, can drive detrimental inflammatory responses.
In line with this notion, mice lacking the cytosolic DNA sensor cyclic GMP AMP synthase (CGAS) 239 have improved early survival after MI along with reduced car diac immune infiltration and consequent pathological tissue remodelling 240 . Cgas −/− mice, Irf3 −/− mice (lacking an effector of CGAS signalling), and Ifnar1 −/− mice (lack ing one of the subunits of the type I interferon receptor) 241 are protected against MI compared with wild type mice, a cardioprotective phenotype that is accompanied by decreased cardiac expression of inflammatory cytokines and chemokines and decreased inflammatory cell infil tration in the myocardium 242 . Similar cardioprotective effects have been documented with hearts from Nlrp3 −/− mice (which lack a core component of the inflamma some) subjected to ischaemia-reperfusion injury ex vivo 243 . Moreover, mtDNA escaping mitophagic degra dation as a consequence of Dnase2 deletion aggravates disease symptoms and progression in a mouse model of pressure overloadinduced cardiomyopathy, a detri mental phenotype that can be partially rescued by Tlr9 codeletion or administration of TLR9inhibiting oligodeoxynucleotides 131 . NLRP3, CGAS, and STING have also been aetiologically involved in the endothelial inflammatory response driven by diet induced obesity and in some models of atherogenesis 235, 244 . Moreover, atherogenesis caused by a high fat diet is inhibited in Apoe −/− Il1r1 −/− mice (which lack both apolipoprotein E and the receptor for IL1β, IL1R1) compared with Apoe −/− mice 245 . By contrast, deletion of Il1rn (encoding an endogenous inhibitor of IL1R1) aggravates consid erably the disease pathogenesis in Apoe −/− mice, whereas Apoe −/− mice engineered to overexpress Il1rn are largely protected from high fatdiet induced atherogenesis 246 . Finally, a common loss offunction variant in P2RX7 (coding for one of the receptors for extracellular ATP) is associated with reduced risk of cardiovascular events in smokers 247 . These studies are only a few examples of how genetic defects in the pro inflammatory sig nalling pathways elicited by mitochondrial DAMPs reduce disease incidence, severity, or progression in rodent models of CVD as a consequence of quenched inflammatory responses.
In line with this notion, pharmacological inhibitors of the signal transduction cascades activated by mito chondrial DAMPs provided beneficial effects in multiple experimental models of CVD. For instance, administra tion of a type I interferon neutralizing antibody pro tected mice against MI to a similar extent as the absence of Irf3 or Ifnar1 (REF. 242 ). Similarly, wild type mice subjected to ischaemia-reperfusion while receiving a pharmacological inhibitor of NLRP3 (16673340) had a significant reduction in infarct size afterwards com pared with their control counterparts 248, 249 . Some degree of cardioprotection has also been observed with the P2RX7 inhibitor Brilliant Blue in rat hearts subjected to ischaemia-reperfusion ex vivo 250 as well as with the TLR9 targeting oligodeoxynucleotide ODN 2088 in rats with spontaneous hypertension 251 . Interestingly, elamipretide binds to and prevents the peroxidation of cardiolipin 252 , and blocking γδ T lymphocytes with a monoclonal anti body specific for killer cell lectin like receptor subfamily K member 1 (KLRK1) reportedly attenuates ischaemiareperfusion injury in a cardiac transplantation model in rats 253 . However, whether elamipretide influences the capacity of cardiolipin to activate γδ T lympho cytes remains to be elucidated. Although multiple anti inflammatory agents are currently available for the treatment of CVD, they all operate by either inhibiting immune cell activation (as in the case of corticosteroids) or by blocking the production of pro inflammatory eicosanoids (as in the case of NSAIDs) 254, 255 . To the best of our knowledge, no therapeutic agent designed to inter cept DAMP emission from mitochondria or specifically block the downstream signalling cascades has reached clinical development.
Regulated cell death.
A prominent aetiological com ponent of multiple cardiovascular disorders, including HF, MI, and atherosclerosis, is the demise of cells dam aged beyond recovery 15 , generally occurring via multi ple, highly interconnected signalling cascades 4 (box 3).
Widespread and irreversible mitochondrial dysfunction culminating with the permeabilization of mitochondrial membranes has a central role in apoptosis, MPT driven regulated necrosis, and parthanatos
256
, de facto contrib uting to pathological tissue loss in the context of CVD 15 . In line with this notion, mice bearing genetic alterations of the molecular apparatus for RCD are protected (at least to some degree) against multiple cardiovascular patholo gies. For instance, Bbc3 −/− mice lack one of the upstream activators of intrinsic apoptosis and have increased resistance to ischaemia-reperfusion injury compared with their wild type littermates 257 . Similarly, mice overexpressing Bcl2, encoding the apoptosis regulator BCL2, have mitigated MI upon ischaemia-reperfusion injury 258 . Ppif −/− mice, which lack the crucial component for MPT driven regulated necrosis CypD, are protected against cardiac ischaemia-reperfusion injury 259, 260 , angiotensin IIinduced cardiomyopathy 261 , and arrhyth mia (in this last case, perhaps also linked to preserved Ca 2+ fluxes) 262 . The deletion of Parp1, which encodes poly(ADP ribose) polymerase 1 (a nuclear DNA repair enzyme that is required for parthanatos), mediates bene ficial effects in mouse models of ischaemia-reperfusion injury 263, 264 and atherogenesis 265 . Moreover, both Ripk3 −/− mice (which lack a critical regulator of necroptosis) and mice engineered to overexpress dominant negative CaMKII in the heart are protected against ischaemiareperfusion injury and the cardiotoxic effects of doxo rubicin 266 . These findings link the molecular machinery for necroptosis, which normally proceeds independently γδ T lymphocytes small subsets of T cells expressing a rather invariant variant of the T cell receptor and mostly operating at the interface between innate and adaptive immunity.
Eicosanoids large family of arachidonic acid derivatives involved in the regulation of multiple biological processes, including the recruitment and activation of immune cells.
Apoptosis
Form of RCD initiated by extracellular or intracellular cues that is precipitated by the sequential activation of various members of the caspase protein family.
Parthanatos
Necrotic variant of RCD driven by PARP1 hyperactivation and precipitated by the consequent bioenergetic catastrophe coupled to enzymatic DNA degradation.
of mitochondria 256 , to mitochondrial dysfunction and consequent MPT driven necrosis.
Extraordinary efforts have also been dedicated to the development of clinically useful inhibitors of RCD for cardioprotective purposes 267 , with rather dismal results. Indeed, although dozens of compounds targeting distinct modules of the molecular machinery for RCD have been successfully synthesized and demonstrated to mediate beneficial effects in experimental models of CVD 267 , none of these agents is currently approved for clinical use. Among other approaches, promising preclinical results in animal models of CVD have been obtained with caspase inhibitors, including: the pan caspase blockers Z VADFMK 268 and MX1013 (REF. 269 ); inhibi tors of the core activator of intrinsic apoptosis, apoptosis regulator BAX (BAX), including a cell permeant peptide derived from the endogenous BAX inhibitor BCL2 like protein 1 (BCL2L1) 270 , as well as the two small mol ecules Bci1 and Bci2 (although these compounds were tested only in rodent models of brain ischaemia) 271 ;
inhibitors of serine protease HTRA2, mitochon drial (HTRA2), such as the small molecule UCF101
(REFs 272,273 ); molecules that preserve the integrity of the respiratory chain in the course of RCD, including mul tiple 2sulfonyl pyrimidinyl derivatives (although these compounds have been investigated only in rodent mod els of neurodegeneration) 274, 275 ; PARP1 inhibitors such as 3aminobenzamide 263 ; and inhibitors of MPT driven necrosis, including TRO40303 (a small molecule spe cific for translocator protein (TSPO) 276 ), cinnamic ani lides (the precise molecular target of which remains to be determined 277 ), and the CypD targeting compounds cyclosporine A, Debio025, NIM811, and sanglifehrin A (REF.
278
). Most of these molecules never reached clinical development, often owing to specificity or bioavailability issues 267 . Conversely, both TRO40303 and cyclosporine A have been investigated for their clinical benefits in patients undergoing percutaneous coronary interven tion for acute MI 279, 280 . However, despite considerable enthusiasm elicited by the release of efficacy data from the first randomized clinical trial to test cyclosporine A for this indication 280 , subsequent studies did not docu ment clinical benefits 281, 282 . Similarly, TRO40303 seems to be well tolerated but devoid of clinical efficacy 283, 284 . To the best of our knowledge, the clinical development of TRO40303 has been discontinued. By contrast, a large number of clinical trials are ongoing to test the therapeu tic effects of cyclosporine A. The vast majority of these studies, however, are aimed at investigating the activity of cyclosporine A as an immunosuppressant rather than as an MPT inhibitor. Indeed, cyclosporine A is approved by the FDA to prevent and treat graft versushost dis ease after bone marrow transplantation, the rejection of kidney, heart, and liver transplantation, and a panel of autoimmune disorders 285, 286 . Of note, the vasodilator nicorandil, which is approved in several countries for the treatment of angina, reportedly potentiates ischaemic preconditioning, at least in some experimental models, by inhibiting MPT 287 . Clinical data from a few studies indicate that nicorandil (which was not conceived as an MTA) might confer cardioprotection after MI [288] [289] [290] , a possibility that remains under scrutiny.
Mitochondrial microRNAs. Most (if not all) aspects of mitochondrial biology are now known to be subjected to epigenetic regulation by microRNAs (miRNAs) 291 . Importantly, this process occurs not only in the nucleus but also in the mitochondrial matrix, where all the components of the molecular apparatus for miRNA dependent gene silencing are present 292 . Both nuclear miRNAs and mitochondrial miRNAs (also known as mitomiRs) have been implicated in the pathogenesis of multiple cardiovascular disorders 291 . The co deletion of the sequences encoding miR181c and miR181d mediated cardioprotective effects in a mouse model of ischaemia-reperfusion injury, potentially linked to preserved levels of the mitochondrially encoded cytochrome c oxidase subunit 1 (MT CO1) and amelior ated respiratory functions 293 . Overexpression of miR30b in mouse cardiomyocytes decreases infarct size after ischaemia-reperfusion injury, reflecting the ability of miR30b to downregulate CypD levels and microRNAs (miRNAs). small non-coding RNA molecules that regulate the expression of target genes at the transcriptional or post-transcriptional level.
Box 3 | Mechanistic notions on regulated cell death mammalian cells exposed to very harsh microenvironmental conditions (such as extreme temperatures and elevated osmotic pressures) die in a virtually uncontrollable manner, reflecting the physical breakdown of the plasma membrane. However, this unregulated cell death is fairly uncommon in the context of human pathophysiology. Instead, human cells generally succumb to pathological cues in the context of failing adaptation to stress via regulated cell death (RCD), which ensues the activation of a genetically encoded machinery that determines the kinetics of the process and its immunological correlates. Indeed, according to current models, mammalian cell death is not caused by the activation of specific proteolytic or nucleolytic pathways, as was thought until the early 2010s, but rather by a lethal shortage of ATP coupled to the accumulation of unrepairable oxidative damage to macromolecules, leading to irreversible loss of plasma membrane integrity. Therefore, actual cytoprotection (that is, a reduction in the percentage of cells succumbing to a cytotoxic cue, as opposed to a simple delay in RCD) might not be achievable after cells are committed to death (that is, when cellular functions are compromised beyond recovery) 4, 330 . Irrespective of this (rather debated) point and its major therapeutic implications (see main text), multiple molecular cascades precipitating RCD in mammals have been identified. These signal transduction cascades rely on a dedicated molecular machinery, meaning that they can be retarded (or accelerated) by specific pharmacological or genetic interventions, and include the following:
• extrinsic and intrinsic variants of apoptosis: a caspase 3-dependent pathway optionally involving mitochondrial outer membrane permeabilization.
• mitochondrial permeability transition-driven necrosis: a cyclophilin D-dependent process elicited at the inner mitochondrial membrane.
• Necroptosis: another form of regulated necrosis culminating with plasma membrane permeabilization dependent on mixed lineage kinase domain-like protein (mlKl).
• Ferroptosis: an iron-dependent pathway mediated by uncontrolled lipid peroxidation.
• Parthanatos: a poly(ADP-ribose) polymerase 1-dependent process resulting in a lethal bioenergetic crisis coupled to DNA degradation.
• Pyroptosis: an inflammatory variant of RCD linked to plasma membrane permeabilization by gasdermin protein family members.
• lysosome-dependent cell death: RCD that is initiated by lysosomal breakdown and precipitated by lysosomal hydrolases.
• Autophagy-dependent cell death: a form of RCD aetiologically linked to components of the molecular machinery for autophagy.
• NeTotic cell death: a reactive-oxygen-species-dependent form of RCD restricted to haematopoietic cells and linked to neutrophil extracellular trap (NeT) production.
• entotic cell death: referring to the lysosomal degradation of living cells internalized by other, nonphagocytic cells via an actomyosin-dependent mechanism (entosis) 4, 330 .
NATuRe RevIeWS | CARdiOlOGy thereby impair MPT 294 . Similarly, miR2861 knock down protects the mouse heart from ischaemiareperfusion injury in vivo, a beneficial phenotype potentially linked to upregulation of solute carrier fam ily 25 member 4 (SLC25A4) 295 . Co deletion of the genes encoding miR212 and miR132 provides cardioprotec tion against pressure overloadinduced cardiomyo pathy along with the activation of FOXO3A dependent autophagy 296 . Consistently, cardiomyocyte specific overexpression of miR132, miR199a, miR212, or miR421 in rodents triggers or aggravates CVD along with the induction of mitophagic defects [296] [297] [298] . Nanoparticle based delivery of a miR181c coding vector also leads to cardiac dysfunction by provoking mitochondrial impairment 299 , as does the deletion of mir-150 and the co deletion of miR-181a and miR181b 293, 300 . Altogether, these observations exemplify the intimate links between the epigenetic regulation of gene expression at both mitochondrial and nuclear levels, mitochondrial biology, and CVD.
Several miRNA targeting strategies have been shown to mediate beneficial effects in preclinical models of CVD. The mitochondrial pool of miR378 increases in the course of diabetic cardiomyopathy in mice, and intraperitoneal administration of a miR378 antagonist mediates cardioprotection, linked with the preservation of mitochondrially encoded ATP synthase subunit a (MT ATP6) synthesis 301 . The mitochondrial levels of mitochondrially encoded cytochrome b (MT CYB) are significantly lower in hearts from rats with spontaneous hypertension than in control hearts from Wistar rats, associated with an upregulation in the mitochondrial pool of miR21 (which promotes Cytb translation) 302 . In line with the hypothesis that miR 21 upregulation constitutes a compensatory response to decreased MT CYB levels and consequent ROS overgeneration, intravenous delivery of an adenoviral vector for the overexpression of miR-21 in rats with spontaneous hypertension mediates short term bene ficial effects on systolic blood pressure and long term cardioprotection 302 . miR106a is robustly upregulated in the hypertrophic myocardium, along with a pro found downregulation of MFN2, and data from cul tured cardiomyocytes exposed to miR106a mimics or antagonists suggest that antagonizing miR106a might contribute to the restoration of MFN2 levels and conse quent rescue of mitochondrial functions 303 . miR3245p and miR761 are negative regulators of mitochondrial fission, and intravenous delivery of a miR3245p or miR761 mimic limits apoptotic RCD and tissue dam age in the myocardium of mice exposed to ischaemiareperfusion 304, 305 . Similarly, administration of a miR499 antagonist (which also inhibits mitochon drial fission) exacerbates infarct size in mice exposed to ischaemia-reperfusion 306 . Expression of miR33a and miR33b is markedly increased in human carotid atherosclerotic plaques compared with normal arter ies, and treatment of Apoe −/− mice with miR33 antag onists reduces arterial atherosclerotic lesions along with the normalization of mitochondrial functions 307 . Additional progress is required for miRNA targeting agents to enter clinical development 308 .
Obstacles in the development of MTAs Despite an extraordinary experimental effort spanning over the past 3 decades, virtually no MTAs are currently approved for use in patients with CVD. We surmise that such a dismal situation is linked (at least in part) to pharmacodynamic and pharmacokinetic issues, a hith erto fragmentary knowledge of the molecular mech anisms behind mitochondrial processes, and a rather simplistic appreciation of the pathophysiology of some cardiovascular disorders. . However, both cyclosporine A and sangli fehrin A also enable the binding of peptidyl prolyl cis trans isomerase A (PPIA) to the heterodimeric phosphatase calcineurin, resulting in potent calcineu rin inhibition and consequent complete blockage of T cell activation 309 . With systemic administration, the immunosuppressive effect of cyclosporine A and sanglifehrin A are prominent, as demonstrated by the fact that cyclosporine A is approved for use in various clinical settings as an immunosuppressant 285, 286 . Novel CypD inhibitors that lack immunosuppressive activity such as Debio025 and NIM811 are currently being developed 278 . In addition, attention is being focused on strategies for the targeted delivery of cyclosporine A to the myocardium. In this setting, promising results have been obtained with poly(lactic coglycolic acid) (PLGA) nanoparticles incorporating cyclosporine A, which were more potent than cyclosporine A at limiting ischaemia-reperfusion injury in mice in the absence of alterations in the myocardial recruitment of inflammatory monocytes 310 . Untargeted antioxidants also have specificity issues because, on entering the cell, antioxidants can quench ROS from multiple (not necessarily mitochondrial) sources, which limits the purely mitochondrial activ ity of these compounds. Multiple strategies have been successfully used to target antioxidants specifically to mitochondria, most of which harness the capacity of cationic molecules to accumulate spontaneously within the mitochondrial matrix mediated by the mitochondrial transmembrane potential (Δψ m ) 311, 312 . One of the major issues with this approach, potentially decreas ing its therapeutic value, is that dysfunctional mitochon dria often have decreased Δψ m and, consequently, are unable to accumulate cationic molecules 313 . Alternative techniques for mitochondrial delivery, including the use of lipophilic cationic peptides 314 , also rely on the Δψ m and, therefore, cannot circumvent this issue. Similarly, mitochondrial proteins encoded by the nuclear genome enter the mitochondrial matrix by a Δψ m dependent mechanism 315 . Thus, devising a strategy for the targeted delivery of molecules to dysfunctional mitochondria will be important. The surface properties of permeabilized mitochondria (including PINK1 and PARK2 accumula tion, as well as extensive ubiquitylation) 6 could be useful but remain unexplored in this context.
Another pharmacological obstacle in the devel opment of clinically useful MTAs relates to pharma cokinetics and biodistribution. In the absence of a tissue targeting strategy, systemically administered MTAs are confronted by large numbers of mitochon dria outside the cardiovascular system, which operate (at least to some degree) as a sink to limit bioavail ability at diseased sites. Cardiomyocytes contain more mitochondria than many other cell types 316 , which could potentially favour MTA accumulation, but so do myocytes and neurons, and the skeletal muscle largely exceeds the myocardium in terms of mass. These considerations suggest that some MTAs deliv ered systemically at safe doses cannot reach bioactive levels at the mitochondrial compartment of diseased cells from the cardiovascular system. Strategies to tar get MTAs to specific cells of the cardiovascular system, such as PLGA nanoparticles 310 , might (at least partially) circumvent this obstacle.
Lack of precise mechanistic knowledge. Despite considerable advances in the understanding of many mitochondrial processes involved in the pathogenesis of CVD, precise mechanistic knowledge is often lack ing. Perhaps the best example of our lack of knowledge of mitochondrial processes comes from MPT 317 . The concept that MPT results from the activity of a supra molecular entity assembled at the interface between the inner and outer mitochondrial membranes, generally referred to as the permeability transition pore complex (PTPC), is widely accepted 171 . However, the precise molecular composition of the PTPC remains obscure, and multiple other aspects of the PTPC biology (includ ing its potential links with the F 1 F o ATP synthase) are still a matter of intense debate, despite >2 decades of experimental work on this topic 317, 318 . This lack of pre cise mechanistic knowledge of mitochondrial processes reflects an intrinsic complexity of the system and the lack of good indicators of mitochondrial (dys)function for use in vivo.
Several mitochondrial proteins are strictly required for embryonic development or adult survival, gener ally owing to their essential bioenergetic functions. One notable example is cytochrome c, somatic (CYCS), which functions as an electron shuttle of the respiratory chain 319 . Because Cycs −/− mice die in utero, investigating the role of CYCS in RCD in vivo called for the develop ment of refined genetic models 320 . Similar models have not yet been generated for the vast majority of mito chondrial proteins with a prominent vital function 319 . Another large group of mitochondrial proteins exists in multiple isoforms that have a large degree of genetic redundancy 317 . For instance, the mouse genome encodes at least three distinct variants of the PTPC component adenosine nucleotide translocase (Slc25a4, Slc25a5, and Slc25a31) and of the ATP synthase F o complex sub unit C (Atp5g1, Atp5g2, and Atp5g3) 321, 322 . This genetic redundancy complicates considerably the generation of functional knockout models for in vivo studies, although it also presumably reflects the critical requirement for mitochondrial ATP synthesis for life (implying that complete knockout models might not be viable). In addition, some mitochondrial proteins have functional redundancy, meaning that they can substitute for each other in a specific activity. This functional redundancy seems to be the case for multiple components of the PTPC, at least in some experimental models 317 . These observations exemplify the intrinsic complexity of multiple mitochondrial processes.
Despite the existence of a variety of probes for in vitro use, monitoring mitochondrial function in vivo thus far has proved challenging. Carbonylation of circulating pro teins or lipoproteins has been used to monitor oxidative stress in the context of CVD 323 . However, this technique per se does not enable the identification of the tissue experiencing oxidative damage, nor the precise source of ROS. Measuring the carbonylation of cardiac pro teins, such as myosin binding protein C, cardiac type (MYBPC), might constitute an improved alternative, although this approach also does not enable the iden tification of the ROS source and it can be performed only post mortem 324 . Mass spectrometrybased profil ing of energy metabolites in blood has been proposed as a surrogate biomarker of mitochondrial dysfunc tion in the context of HF 325 , but the wide applicability of these findings remains untested. One promising approach to monitor mitochondrial dysfunction in preclinical models of CVD is provided by the so called MitoTimer mouse, a mouse strain engineered to express a mitochondria targeted mutant of the DsRed fluores cent protein (which shifts to red fluorescence when oxidized) under the control of a cardiomyocyte specific promoter 326, 327 . MitoTimer enables the study of mito chondrial structure, redox state, and mitophagic dis posal by fluorescence microscopy on fixed tissue 326, 327 . Finally, multiple radioactive tracers are being developed to monitor mitochondrial functions in real time in the setting of CVD 26, 328 . These molecules, some of which are already approved for use in humans (for different appli cations), might constitute preferential tools to study the links between mitochondrial dysfunction and multiple forms of CVD in patients.
Limited appreciation of the multifactorial nature of CVD. All cardiovascular disorders are complex patho logical entities that develop in the context of multiple cel lular, histological, and systemic processes including (but not limited to): an initial attempt of cells to cope with potentially detrimental perturbations of their micro environment for the restoration of cellular homeostasis; the failure of such an adaptive mechanism, culminat ing with the initiation of RCD coupled to inflammatory responses; the establishment of acute local inflamma tion after the recruitment of immune cells, at least partly linked to the disposal of dead cells and cell remnants; and the initiation of repair processes, either culminating with resolved inflammation and fibrosis (if the initial perturbation of homeostasis is relieved) or proceeding chronically along with a continuous wave of RCD and low degree inflammation (if the initial perturbation of homeostasis persists). This process is further complicated by at least four additional elements. First, the entire process involves not only cells from the cardiovascular system (the main target of clinically available drugs) but also stromal cells and, to a greater extent, immune cells 230 . Although the contribution of immune cells to some forms of CVD such as atherosclerosis was appreciated long ago 14 , the role of innate immune mechanisms such as dysregu lated type I interferon signalling in HF has just begun to emerge 242 . Second, there is a critical, and we believe often underestimated, time component in the pathogenesis of most, if not all, cardiovascular disorders. As an exam ple, ischaemia-reperfusion injury is often viewed (and experimentally modelled) as a rather uniform entity, and potential therapeutic interventions administered at reperfusion are tested for their capacity to decrease infarct size or improve survival. Although these mod els are widely viewed as clinically relevant (patients with acute MI indeed enter intensive care during the ischaemic phase), they are intrinsically unable to dis sect the sequence of events initiated at reperfusion, many of which have a direct effect on patient survival. Third, CVD generally develops in elderly individuals, along with a variety of comorbidities, including (but not limited to) obesity, diabetes, and declining immune functions 329 . These disorders affect not only the natu ral progression of CVD but also its sensitivity to treat ment 329 . However, only a few animal models of CVD that are currently available recapitulate such comorbidities. Fourth, many cellular processes involved in the patho genesis of CVD have a considerable degree of redun dancy. For instance, after mammalian cells commit to RCD, inhibiting one single variant of the process only delays (rather than prevents) cellular demise, and it has been argued that actual cytoprotection can be achieved only in the course of adaptive responses to perturba tion of homeostasis 330 . This concept casts doubts on the hypothesis that pharmacologically blocking RCD in diseased cardiovascular cells provides clinical benefits (which has been intensively tested with dismal results) and suggests that improving the ability of healthy cells to cope with perturbations of homeostasis constitutes a robust prophylactic strategy. Interestingly, an abundant literature established a robust interconnection between various components of the molecular machineries for RCD and inflammation 331 . This finding opens the intriguing possibility that modulating RCD pathways in diseased cardiovascular cells might affect the consequent inflammatory responses, de facto mediating beneficial effects via cell extrinsic circuitries 332 . Such a possibility awaits urgent experimental validation. In support of this notion, cyclosporine A, one of the few MTAs cur rently approved for use in clinics (although not for the treatment of CVD), robustly inhibits MPT and mediates potent anti inflammatory effects.
Altogether, these observations indicate that improved pharmacodynamic and pharmacokinetic properties, a refined mechanistic knowledge of mito chondrial processes, and a reconsideration of the patho genesis of (at least some) cardiovascular disorders, together with a redesigned pharmacological audit trail (Fig. 3) , are instrumental for the development of novel MTAs with clinical use.
Conclusions
Robust genetic data demonstrated a crucial role for mito chondrial dysfunction in the pathogenesis of multiple cardiovascular disorders. Nonetheless, the development of MTAs for use in patients with CVD has been rather dismal. Thus far, great attention has been focused on modulating a single mitochondrial process in cells from cardiovascular compartments, and the immunological correlates of RCD and RCD driven inflammation have
Pharmacological audit trail
Rational framework to guide the development of novel therapeutic agents that involves assessing the risk of failure at any specific stage. To develop novel, clinically useful mitochondria-targeting agents for the treatment or prevention of cardiovascular disease, it is paramount to delineate upfront: the therapeutic paradigms in which mitochondrial dysfunctions cause or aggravate cardiovascular disease; specific patient subsets in which such alterations might have a predominant role in disease pathogenesis; the cell populations that are affected by mitochondrial dysfunction (the diseased cells, which do not necessarily overlap with the cell populations that are commonly linked to disease pathogenesis); and the nature of mitochondrial dysfunction and how such a dysfunction affects the biology of diseased and/or other cells from the cardiovascular or immune system (bystander cells). This analysis will potentially enable the identification of a mitochondrial target for pharmacological interventions and a candidate drug. Delivery platforms tailored to the mitochondrial compartment of diseased cells will have to be developed and characterized in conventional pharmacokinetic and pharmacodynamic studies, followed by an assessment of mitochondrial, cellular, and microenvironmental parameters in both the diseased and bystander cell populations. In the absence of biological efficacy , the choice of molecular target, drug candidate, and/or delivery platforms will have to be re-evaluated, with particular attention for immunological disease correlates. Otherwise, a cardiovascular response followed by improved patient survival might emerge. In the absence of either or both, the entire therapeutic paradigm and/or patient selection should be fully reconsidered.
been fairly overlooked. We firmly believe that systemat ically addressing CVD as a complex phenomenon that is intimately connected with inflammatory responses will be instrumental for the development of novel agents with clinical applications. Alongside, endowing MTAs with superior pharmacological specificity and acquiring additional knowledge on the precise molec ular mechanisms linking mitochondrial dysfunction to CVD pathogenesis, potentially aiming at strategies that simultaneously modulate multiple aspects of the disease, will be paramount. In this context, it will be important to evaluate carefully the cardiovascular effects (or lack thereof) of precise genetic interventions targeting mito chondrial functions on the basis of the age and sex of the animals and the potential existence of compensa tory pathways, especially based on functional (rather than genetic) redundancy, as well as evaluate the effects in the context of pathologically relevant comorbidities. Deleting specific mitochondria relevant genes from the embryonic myocardium has consequences that the same intervention does not provoke in the adult 97 , which is particularly relevant for the development of pharmacological interventions. Data accumulating over the past decade point to considerable differences in the sensitivity of male versus female rodents to experimen tal CVD, and epidemiological data in humans support similar conclusions 333, 334 , but little work has been done with specific reference to mitochondrial dysfunction 335 . Moreover, whereas the effect of genetic redundancy on a specific mitochondrial pathway can be addressed with (relatively complex, but feasible) co deletion and/or depletion strategies [336] [337] [338] , identifying (and investigating) functional redundancy is far more complex. Finally, an unmet need exists for new rodent models that faithfully recapitulate the comorbidities that normally accompany CVD in humans 329 . In conclusion, although the route to the identification of clinically useful MTAs is long and tortuous, a large amount of evidence suggests that mito chondrial dysfunction remains a promising target for the treatment of multiple forms of CVD.
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